Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Alemtuzumab in Multiple Sclerosis Patients from Prior Genzyme Trials
2009-010788-18Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Sanofi. Primary endpoint: Safety of long-term alemtuzumab treatment. Started Jul 2009; status: completed.
02
Drugs
alemtuzumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2009-010788-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010788-18.